Viltolarsen
Viltolarsen, sold under the brand name Viltepso, is a medication used for the treatment of Duchenne muscular dystrophy (DMD).[1] Viltolarsen is an antisense oligonucleotide.[1]
| Clinical data | |
|---|---|
| Trade names | Viltepso |
| Other names | NS-065/NCNP-01 |
| License data |
|
| Drug class | Antisense oligonucleotide |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C244H381N113O88P20 |
| Molar mass | 6924.910 g·mol−1 |
The most common side effects include upper respiratory tract infection, injection site reaction, cough and fever.[1]
Viltolarsen was approved for medical use in the United States in August 2020.[1] Viltolarsen is the second approved targeted treatment for people with this type of mutation in the United States.[1] Approximately 8% of people with DMD have a mutation that is amenable to exon 53 skipping.[1]
Medical uses
Viltolarsen is indicated for the treatment of Duchenne muscular dystrophy (DMD) in people who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.[1]
DMD is a rare genetic disorder characterized by progressive muscle deterioration and weakness.[1] It is the most common type of muscular dystrophy.[1] DMD is caused by mutations in the DMD gene that results in an absence of dystrophin, a protein that helps keep muscle cells intact.[1] The first symptoms are usually seen between three and five years of age and worsen over time.[1] DMD occurs in approximately one out of every 3,600 male infants worldwide; in rare cases, it can affect females.[1]
Adverse effects
The most common side effects include upper respiratory tract infection, injection site reaction, cough and fever.[1]
Although kidney toxicity was not observed in the clinical studies, the clinical experience is limited, and kidney toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides.[1]
History
Viltolarsen was evaluated in two clinical studies with a total of 32 participants, all of whom were male and had genetically confirmed DMD.[1] The increase in dystrophin production was established in one of those two studies, a study that included sixteen DMD participants, with eight participants receiving viltolarsen at the recommended dose.[1] In the study, dystrophin levels increased, on average, from 0.6% of normal at baseline to 5.9% of normal at week 25.[1]
The U.S. Food and Drug Administration (FDA) concluded that the applicant's data demonstrated an increase in dystrophin production that is reasonably likely to predict clinical benefit in people with DMD who have a confirmed mutation of the dystrophin gene amenable to exon 53 skipping.[1] A clinical benefit of the drug has not been established.[1] In making this decision, the FDA considered the potential risks associated with the drug, the life-threatening and debilitating nature of the disease, and the lack of available therapies.[1]
The application for viltolarsen was granted priority review designation and the FDA granted the approval to NS Pharma, Inc.[1]
References
- "FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation". U.S. Food and Drug Administration (FDA) (Press release). 12 August 2020. Retrieved 12 August 2020.
External links
- "Viltolarsen". Drug Information Portal. U.S. National Library of Medicine (NLM).